The stock of Zura Bio Ltd (ZURA) has seen a 15.69% increase in the past week, with a 9.84% gain in the past month, and a -21.33% decrease in the past quarter. The volatility ratio for the week is 10.57%, and the volatility levels for the past 30 days are at 8.01% for ZURA. The simple moving average for the last 20 days is 14.06% for ZURA stock, with a simple moving average of 5.96% for the last 200 days.
Is It Worth Investing in Zura Bio Ltd (NASDAQ: ZURA) Right Now?
Additionally, the 36-month beta value for ZURA is 0.15. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ZURA is 32.89M and currently, short sellers hold a 12.22% ratio of that float. The average trading volume of ZURA on September 02, 2024 was 306.71K shares.
ZURA) stock’s latest price update
The stock price of Zura Bio Ltd (NASDAQ: ZURA) has plunged by -1.20 when compared to previous closing price of 4.18, but the company has seen a 15.69% gain in its stock price over the last five trading sessions. investorplace.com reported 2024-07-19 that Undervalued biotech stocks will always be relevant for the savvy investor. The biotech world is evolving rapidly, with pharmaceutical giants tirelessly building on their pipelines and technologies.
Analysts’ Opinion of ZURA
Many brokerage firms have already submitted their reports for ZURA stocks, with Piper Sandler repeating the rating for ZURA by listing it as a “Overweight.” The predicted price for ZURA in the upcoming period, according to Piper Sandler is $26 based on the research report published on May 03, 2024 of the current year 2024.
Ladenburg Thalmann, on the other hand, stated in their research note that they expect to see ZURA reach a price target of $10. The rating they have provided for ZURA stocks is “Buy” according to the report published on October 10th, 2023.
Oppenheimer gave a rating of “Outperform” to ZURA, setting the target price at $17 in the report published on August 25th of the previous year.
ZURA Trading at 14.03% from the 50-Day Moving Average
After a stumble in the market that brought ZURA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.90% of loss for the given period.
Volatility was left at 8.01%, however, over the last 30 days, the volatility rate increased by 10.57%, as shares surge +13.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +19.36% upper at present.
During the last 5 trading sessions, ZURA rose by +15.69%, which changed the moving average for the period of 200-days by +3.25% in comparison to the 20-day moving average, which settled at $3.65. In addition, Zura Bio Ltd saw -11.56% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZURA starting from Ploos van Amstel Arnout, who purchase 80,000 shares at the price of $6.20 back on May 17 ’24. After this action, Ploos van Amstel Arnout now owns 100,000 shares of Zura Bio Ltd, valued at $496,000 using the latest closing price.
Howell Michael, the of Zura Bio Ltd, purchase 7,987 shares at $3.13 during a trade that took place back on Apr 22 ’24, which means that Howell Michael is holding 7,987 shares at $24,999 based on the most recent closing price.
Stock Fundamentals for ZURA
The total capital return value is set at -0.24. Equity return is now at value -26.74, with -19.90 for asset returns.
Currently, EBITDA for the company is -62.64 million with net debt to EBITDA at 4.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.57.
Conclusion
In conclusion, Zura Bio Ltd (ZURA) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
